Physician
Retinovitreous Associates LTD
Retinovitreous Associates LTD was paid $5.10M by Medicaid between Jan 2018 and Dec 2024, across 19 billing codes. Its largest line is 67028, Intravitreal injection of a pharmacologic agent — 46% of everything it billed.
33Billing provider infoRETINOVITREOUS ASSOCIATES LTD
PLYMOUTH MEETING, PA 19462
PLYMOUTH MEETING, PA 19462
33aNPI1659326452assigned 05/23/2006
33bProvider typeRetina Specialist (Ophthalmology) Physician
28Total paid$5.10M
24GClaims112,145
24DCodes billed19
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Retina Specialist (Ophthalmology) Physician providers in Pennsylvania
Rank by total paid#1 of 19
Median peer was paid$14K
This provider vs. median363×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,110 | $30K | |
| 2019 | 294 | $10K | |
| 2020 | 3,592 | $366K | |
| 2021 | 23,443 | $1.92M | |
| 2022 | 26,350 | $839K | |
| 2023 | 29,742 | $994K | |
| 2024incomplete | 24,614 | $938K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 67028 | Intravitreal injection of a pharmacologic agent | 46% | 29,385 | 24,404 | $2.36M |
| 92134 | 19% | 49,881 | 46,106 | $969K | |
| J0178 | Injection, aflibercept, 1 mg | 18% | 8,646 | 8,037 | $935K |
| J2778 | Injection, ranibizumab, 0.1 mg | 9.0% | 4,072 | 3,746 | $456K |
| J9035 | Injection, bevacizumab, 10 mg | 2.6% | 6,237 | 6,032 | $131K |
| 92250 | 2.0% | 2,369 | 2,265 | $100K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | 1.3% | 9,006 | 8,387 | $68K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | <1% | 414 | 406 | $22K |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | <1% | 71 | 68 | $19K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 683 | 658 | $13K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | <1% | 423 | 414 | $12K |
| 67228 | <1% | 15 | 14 | $6K |
7 more codes
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSHEPPARD, COURTNEY (CAO/CFO)
| Provider | Location | Paid |
|---|---|---|
| Associated Retinal Surgeons, PA | Cherry Hill, NJ | $2.58M |
| Retinovitreous Associates LTD | Wilmington, DE | $508K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.